Search - tctmd.com

Displaying 1 - 20 of 498

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

December 29, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

December 29, 2016

News Daily News

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

December 12, 2016

News Daily News

Patients With A-fib Still Have High Mortality Risk After Appropriate Anticoagulation Is Started

December 05, 2016

News Conference News AHA 2016

Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No – A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

October 07, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Michael O'Riordan

October 03, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

September 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.